Page 1 of 9Free preview · 1–5

About this document

This chapter excerpt from Vitamin and Mineral Safety, 3rd Edition (2013), reviews vitamin D forms, metabolism, bioavailability, deficiency, and toxicity. It compares safety assessments by EVM, IOM, and EFSA with CRN recommendations. The quantitative summary reports CRN's supplemental upper limit of 250 μg (10,000 IU) per day, IOM and EFSA total-intake upper limits of 100 μg (4,000 IU) per day, and EVM's supplemental guidance level of 25 μg (1,000 IU) per day. References support the discussion of intake levels, hypercalcemia, and risk assessment.

Free preview text

The first 5 pages, shown as text so search engines and readers can find this document.

Page 1

EXCERPTED FROM: Vitamin and Mineral Safety 3rd Edition (2013) Council for Responsible Nutrition (CRN) www.crnusa.org 1 Vitamin D Introduction Vitamin D is required in quantities smaller than any other fat-soluble vitamin. The major forms of vitamin D are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D has been described as a pro-hormone or sunshine-dependent vitamin. Some dietary vitamin D2 comes from plants, but the largest contribution to dietary intake of vitamin D is the vitamin D3 in fish liver oils, eggs, milk, and liver. Milk is commonly fortified with 10 μg (400 IU) of vitamin D3 per quart. Extremely high potency (40,000 to 50,000 IU) products—sold as prescription or sometimes over the counter—often consist of vitamin D2. Most vitamin D dietary supplements contain vitamin D3. The conversion of international units to metric weights is extremely simple for both vitamin D2 and D3: 1 μg equals 40 IU; 0.025 μg equals 1 IU. Vitamin D3 (or D2) from endogenous production, foods, or vitamin supplements is inert and must undergo two hydroxylation reactions in the body for activation. The first occurs in the liver and the second in the kidneys. The first hydroxylation produces 25-hydroxy vitamin D (25[OH] D) and the second produces the active hormone 1,25-dihydroxy vitamin D (1,25-di[OH]D). Because the plasma half-life of the active form 1,25-di(OH)D is short (approximately 15 hours), the best indicator of vitamin D status is 25-(OH)D (plasma half-life of 15 days or so). Because of these pharmacokinetics, most vitamin D in plasma is present as 25(OH)D, also called calcidiol, and its concentration has become the standard index of vitamin D status. 1,25-di(OH)D (calcitriol), the activated vitamin, regulates intestinal absorption and plasma concentration of calcium. As calcitriol, vitamin D is fundamentally involved in the formation of bone, and so its deficiency can lead to rickets in children or osteoporotic changes in adults. Bioavailability Although it can be synthesized in the body with sufficient exposure to sunlight or another ultraviolet (UV) light source, most people are not exposed to such UV light in consistent and

Page 2

EXCERPTED FROM: Vitamin and Mineral Safety 3rd Edition (2013) Council for Responsible Nutrition (CRN) www.crnusa.org 2 sufficient quantities. No extra vitamin D is required when skin exposure to UV light is ample; but without such exposure, a person is completely dependent on ingested vitamin D. The UV component of sunlight converts internally produced 7-dehydrocholesterol naturally present in the skin to cholecalciferol (vitamin D3) (Life Sciences Research Office [LSRO] 1978; Holick 1999). Although adequate UV light exposure can provide sufficient vitamin D, many elderly persons have limited sunlight exposure, inadequate dietary sources, and a decreased ability to activate vitamin D, making them susceptible to vitamin D deficiency (Gloth et al. 1995; Holick 1999). Elderly people are likely to have substantially increased needs for dietary vitamin D because of their decreased mobility and exposure to sun and decreased activation in the liver and kidneys. Thus, the nutritional need for dietary vitamin D depends on the biosynthesis in the skin, which in turn is influenced by time of exposure to sunlight, season (sun intensity and clothing), latitude, skin pigmentation, and the use of sunscreens. Safety Considerations The formation of vitamin D in the skin is slowed once dietary vitamin D intakes are sufficient and blood levels of the activated forms are high. Therefore, excess exposure to sunlight does not lead to vitamin D toxicity (Holick 1999; Hathcock et al. 2007). Dietary vitamin D can, however, produce toxic effects when consumed in very large quantities, especially over an extended period of time. Studies have shown that subjects with abnormally high levels of vitamin D intake can suffer from a wide range of signs and symptoms, from dehydration to permanent mineral deposits in soft tissues, including muscle, heart, kidney, and cartilage. Continued intake of toxic levels can have severe and persistent adverse consequences. The widespread occurrence of vitamin D overdoses in British children just after World War II, caused by consumption of excessively fortified milk, led health professionals to be extremely conservative in estimating safe levels for vitamin D.

Page 3

EXCERPTED FROM: Vitamin and Mineral Safety 3rd Edition (2013) Council for Responsible Nutrition (CRN) www.crnusa.org 3 Prolonged intake of excess vitamin D may lead to predictable increases in plasma 25-hydroxy vitamin D concentrations (Institute of Medicine [IOM] 2011), and the increase is directly proportional to the vitamin D dose (Barger-Lux et al. 1998). Treatment with vitamin D or 25- hydroxy vitamin D does not generally increase the serum concentrations of the active metabolite (calcitriol, 1-alpha,25-dihydroxycholecalciferol, or 1,25-dihydroxy vitamin D) (Barger-Lux et al. 1998). Nonetheless, excess vitamin D can have toxic effects, perhaps because of the increases in blood concentrations of 25-hydroxy vitamin D, a form that can overstimulate intestinal absorption of calcium and cause excessive calcium mobilization from bone and hypercalcemia (Norman 1996; Holick 1999). Although the IOM considers hypercalcemia to be the critical effect in vitamin D toxicity, no clinical trials have used levels sufficiently high to produce such high blood levels of calcium. All such evidence comes from reports of anecdotal cases of accidental massive overdoses. The amount of daily vitamin D ingestion needed to produce adverse effects varies widely. In most adults, daily intake in excess of 50,000 IU (1.25 mg) is needed to produce toxicity (Miller and Hayes 1982). Clinical trials in the last decade or so have found no hypercalcemia in subjects in subject taking 10,000 IU (250 μg) in long-term clinical trials. In certain disease conditions such as sarcoidosis, mycobacterium infections such as tuberculosis, or idiopathic hypercalcemia, toxicity can occur at levels of vitamin D intake lower than those in healthy persons. A causal relationship between excess vitamin D intake and hypercalcemia is unlikely, although people with idiopathic hypercalcemia may be subject to adverse effects of vitamin D at lower intakes than are comfortably tolerated by healthy individuals (Expert Group on Vitamins and Minerals [EVM] 2003). Body size matters. One study has found that in children of unspecified body weight (probably between 10 and 30 kg), the amount of dietary vitamin D causing adverse effects may be as low as 2,000 to 4,000 IU (50 to 100 μg) per day. In full-term infants, adverse effects are reported to occur with intakes as low as 1,800 IU (45 μg) per day (Chesney 1989), but no adverse effects occurred in a 6-month study of infants given 1,600 IU per day (Fomon et al. 1966). Numerous reports confirm a variety of adverse effects at very high intakes when vitamin D is used as a drug, whether administered parenterally or in activated forms (Nanji 1985; Goldman and

Page 4

EXCERPTED FROM: Vitamin and Mineral Safety 3rd Edition (2013) Council for Responsible Nutrition (CRN) www.crnusa.org 4 Wheeler 1987; Schwartzman and Franck 1987; Allen and Shah 1992; Boulard et al. 1994; Oymak et al. 1994; Matsukawa et al. 1995). These circumstances do not relate to the usual oral intakes of vitamin D from foods or dietary supplements, and such reports provide no useful information about the safety of dietary sources of vitamin D. Official Reviews Expert Group on Vitamins and Minerals (EVM 2003). The UK’s EVM did not find the data sufficiently compelling to identify a NOAEL or a LOAEL. Instead, it set a guidance level of 25 μg, based on studies by Vieth et al. (2001) at 100 μg and Johnson et al. (1980) at 50 μg. The EVM concluded that long-term use of supplements of 25 μg is “well tolerated,” but did not establish a safe upper limit. IOM (2011). The IOM has established a UL of 100 μg (4,000 IU) vitamin D, based on downward extrapolation from the NOAEL of 250 μg (10,000 IU), as derived from multiple clinical trials in a risk assessment using UL methodology (Hathcock et al. 2007). To take into account uncertainties from emerging data regarding all-cause mortality, chronic disease risk, and falls at serum 25(OH)D levels of approximately 75 to 125 nmol per L, the IOM considered the findings of Heaney et al. (2003) in establishing a UL. In this study, intakes of 5,000 IU vitamin D per day for 160 days resulted in serum 25(OH)D levels that did not exceed 150 nmol per L and serum calcium levels within normal ranges. The UL was set at 20 percent below 5,000 IU (i.e.¸4,000 IU) because of the uncertainties surrounding the data and the reliance on one study. The IOM intended “not to determine that certain levels of intake definitively cause harm, but rather to decide whether the emerging data were sufficiently compelling to warrant caution relative to vitamin D intakes.” The IOM approach, however, did not take into account the ample caution built into the NOAEL and the UL method in the peer-reviewed literature (Hathcock et al. 2007). In addition, the IOM examined the data related to several endpoints but based their UL of 4,000 IU on only one of several different adjustments of the data on all-cause mortality in several different age, gender, and disease groups (Visser et al. 2006).

Page 5

EXCERPTED FROM: Vitamin and Mineral Safety 3rd Edition (2013) Council for Responsible Nutrition (CRN) www.crnusa.org 5 For example, Figure 6-1 of the IOM report graphs the hazard ratio of all-cause mortality against serum 25(OH)D (nmol per L), with adjustments for various health and age factors. All risk curves are high when vitamin D status is low and progress downward to low points as vitamin D status increases. Although the two right side points are equal, there is no hint of a reverse J-shape to the curves—and thus no indication that that vitamin D status up to 82 nmol per L causes any harm. Figure 6-2 plots relative risk of death in elderly people against baseline serum 25(OH)D, graphed with four different adjustments for factors that could influence health. Only Model 4 shows definite increases in risk as serum 25(OH)D reaches 75+ nmol per L. This model adjusts the data for gender, age, education, chronic disease, serum creatinine concentration, and lifestyle variables including smoking status, alcohol consumption, and physical activity; it adjusts for all these plus frailty indications including physical activity, low serum albumin concentration, and low serum total cholesterol concentration. Figure 6-3 displays the results of adjustment to the data similar to that in Figure 6-2’s Model 4, and there is no increase in risk with serum 25(OH)D concentrations up to 80.3+. There was no discussion of the likelihood of a random “significant” effect when more than 20 adjustments are made to the primary data. EFSA (2012). EFSA considered that a daily vitamin D dose of 250 μg per day reflects a NOAEL, based on two studies in which doses of 234 to 275 μg vitamin D3 per day for 8 weeks to approximately 5 months did not result in hypercalcemia in healthy young men (Barger-Lux et al. 1998; Heaney et al. 2003). A UF of 2.5 was applied to account for the variation in the sensitivity of the population to potential adverse effects of long-term vitamin D exposure, the short duration of the studies, as well as the small number and characteristics (healthy young men with minimal sun exposure) of the individuals studied. The UL was therefore estimated to be 100 μg per day.

Tags

Doxxly editorial guide

Vitamin D: summary, contents and background

This guide helps you understand the scope of Vitamin D before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.

Summary and overview

Vitamin D is a 9-page documentcredited to Vesna U. Yarrow. This chapter excerpt from Vitamin and Mineral Safety, 3rd Edition (2013), reviews vitamin D forms, metabolism, bioavailability, deficiency, and toxicity. It compares safety assessments by EVM, IOM, and EFSA with CRN recommendations. The quantitative summary reports CRN's supplemental upper limit of 250 μg (10,000 IU) per day, IOM and EFSA total-intake upper limits of 100 μg (4,000 IU) per day, and EVM's supplemental guidance level of 25 μg (1,000 IU) per day. References support the discussion of intake levels, hypercalcemia, and risk assessment. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.

The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of Vitamin D, Vitamin safety, Dietary supplements, Bioavailability, Toxicity, Hypercalcemia, Upper intake limits, Risk assessment with the related resources linked below.

Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.

Key topics and reader takeaways

The catalogue connects this document with Vitamin D, Vitamin safety, Dietary supplements, Bioavailability, Toxicity, Hypercalcemia, Upper intake limits, Risk assessment. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.

A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.

Table of contents and reading guide

The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 9 pages in the player.

  1. Part 1

    Vitamin D

    Use this section of the reading guide to identify how Vitamin D appears in Vitamin D, note important terms, and connect the subject to the wider purpose of the work.

  2. Part 2

    Vitamin safety

    Use this section of the reading guide to identify how Vitamin safety appears in Vitamin D, note important terms, and connect the subject to the wider purpose of the work.

  3. Part 3

    Dietary supplements

    Use this section of the reading guide to identify how Dietary supplements appears in Vitamin D, note important terms, and connect the subject to the wider purpose of the work.

  4. Part 4

    Bioavailability

    Use this section of the reading guide to identify how Bioavailability appears in Vitamin D, note important terms, and connect the subject to the wider purpose of the work.

  5. Part 5

    Toxicity

    Use this section of the reading guide to identify how Toxicity appears in Vitamin D, note important terms, and connect the subject to the wider purpose of the work.

  6. Part 6

    Hypercalcemia

    Use this section of the reading guide to identify how Hypercalcemia appears in Vitamin D, note important terms, and connect the subject to the wider purpose of the work.

  7. Part 7

    Upper intake limits

    Use this section of the reading guide to identify how Upper intake limits appears in Vitamin D, note important terms, and connect the subject to the wider purpose of the work.

  8. Part 8

    Risk assessment

    Use this section of the reading guide to identify how Risk assessment appears in Vitamin D, note important terms, and connect the subject to the wider purpose of the work.

When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.

About Vesna U. Yarrow

Doxxly credits Vesna U. Yarrow as the author or creator of Vitamin D. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.

Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.

About the source organisation

The recorded source for this item is crnusa.org. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.

Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.

Visit crnusa.org

How to read and use this document

Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.

The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.

If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.

Research questions to consider

As you read Vitamin D, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.

A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.

Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.

Explore more Medicine & Wellbeing resources

Frequently asked questions about Vitamin D

Practical answers about reading, downloading and understanding this document on Doxxly.

More in Medicine & Wellbeing